問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Recruiting

List

554Cases

2025-02-07 - 2032-12-31

Phase I/II

Active
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-11-01 - 2029-05-31

Phase III

Active
An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    Tablets Tablets Granules for suspension Granules for suspension

Participate Sites
6Sites

Recruiting5Sites

2024-12-26 - 2028-10-20

Active
A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma

  • Condition/Disease

    Peripheral T-cell Lymphoma

  • Test Drug

    Capsules Frozen Crystal Powder for Injection Injection Tablets

Participate Sites
8Sites

Recruiting8Sites

2024-12-30 - 2031-06-26

Phase III

Active
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

  • Condition/Disease

    Leukemia

  • Test Drug

    Film-coated tablets

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2028-03-01

Phase I

Active
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    subcutaneous injection

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2032-01-31

Phase III

Active
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13)

  • Condition/Disease

    Ovarian Cancer

  • Test Drug

    Frozen Crystal Injection

Participate Sites
7Sites

Recruiting7Sites

2025-02-03 - 2029-12-23

Not yet recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2029-06-30

Phase III

Active
A phase 3, randomized, multicenter, open-label study was conducted to investigate the use of IDRX-42 (GSK6042981) versus Sunitinib in participants with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who had received imatinib treatment (StrateGIST 3).

  • Condition/Disease

    Metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) following treatment with imatinib.

  • Test Drug

    IDRX-42 (GSK6042981) Sunitinib

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2032-01-31

Phase II/III

Active
A phase 2/3, open-label, randomized trial evaluating the efficacy of telisotuzumab adizutecan monotherapy versus osimertinib in patients with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer who have progressed after third-generation EGFR TKI therapy, compared with standard of care. - AndroMETa-Lung-713

  • Condition/Disease

    Subjects with locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after third-generation EGFR TKI treatment

  • Test Drug

    Telisotuzumab Adizutecan (ABBV-400)

Participate Sites
8Sites

Recruiting8Sites

2025-09-23 - 2028-02-13

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    Film-coated tablets Film-coated tablets

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5 56
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB